Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals has announced that under a supply agreement with Solvay Pharmaceuticals, the company has launched the authorized generic version of dronabinol in the 2.5, five and 10mg once daily dosage strengths.
Subscribe to our email newsletter
Dronabinol is the generic version of Solvay Pharmaceuticals’s Marinol CIII capsules, indicated to treat nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
Dronabinol is also indicated to treat anorexia associated with weight loss in patients with acquired immunodeficiency syndrome (AIDS).
Under the terms of the supply agreement, Solvay Pharmaceuticals will supply the dronabinol capsules to the company’s subsidiary, Watson Pharma, which will market, sell and distribute the product in the US. Solvay Pharmaceuticals will receive a share of the profits from Watson’s sales of the generic product in the US market.